A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|82|6|333-340

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.6, 2012-06, pp. : 333-340

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review

By Wong Michael K.   Yang Hongbo   Signorovitch James E.   Wang Xufang   Liu Zhimei   Liu Nathan S.   Qi Cynthia Z.   George Daniel J.  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 537-545

Informa Healthcare

Access to resources Recommend Favorite

Continuous Therapy with Sunitinib in Patients with Metastatic Renal Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 31, Iss. 8-9, 2008-07 ,pp. : 485-485

Karger

Access to resources Recommend Favorite

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-12 ,pp. : 583-586

Karger

Access to resources Recommend Favorite

Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 3, 2015-09 ,pp. : e1-e5

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stevens-Johnson Syndrome Induced by Sorafenib for Metastatic Renal Cell Carcinoma

By  

Urologia Internationalis, Vol. 91, Iss. 4, 2013-08 ,pp. : 482-483

Karger

Access to resources Recommend Favorite